Reslizumab
- Generic Name
- Reslizumab
- Brand Names
- Cinqair, Cinqaero
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 241473-69-8
- Unique Ingredient Identifier
- 35A26E427H
- Background
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils . Elevated levels of eosinophi...
- Indication
Indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
- Associated Conditions
- Severe Eosinophilic Asthma
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath